Leqvio vs Vascepa
A side-by-side look at two cardiovascular medications advertised on TV. Informational only — not medical advice.
| US Leqvio | US Vascepa | |
|---|---|---|
| Generic name | inclisiran | icosapent ethyl |
| Drug class | siRNA PCSK9-Lowering Therapy | Omega-3 Fatty Acid (EPA) |
| Treats | High cholesterol, cardiovascular disease | High triglycerides, cardiovascular risk reduction |
| Category | Cardiovascular | Cardiovascular |
| Manufacturer | Novartis | Amarin |
| Year approved | 2021 | 2012 |
| FDA warning | No boxed warning | No boxed warning |
| Est. TV ad spend | $90M | $90M |
| Common side effects | Injection site reactions, Joint pain, Urinary tract infection, Shortness of breath | Atrial fibrillation, Bleeding risk, Joint pain, Swelling |
Frequently asked questions
Is Leqvio or Vascepa better?
Neither is universally "better." Leqvio (inclisiran) and Vascepa (icosapent ethyl) are both used for cardiovascular, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Leqvio and Vascepa?
Leqvio is a siRNA PCSK9-Lowering Therapy made by Novartis, while Vascepa is a Omega-3 Fatty Acid (EPA) made by Amarin. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Leqvio has the larger estimated TV advertising budget of the two.